The effect of MElatonin on Depressive symptoms, Anxiety, CIrcadian and Sleep disturbances in patients after acute coronary syndrome (MEDACIS): study protocol for a randomized controlled trial

Michael Tvilling Madsen, Anders Isbrand, Ulla Overgaard Andersen, Lars Juel Andersen, Mustafa Taskiran, Erik Simonsen, Ismail Gögenur, Michael Tvilling Madsen, Anders Isbrand, Ulla Overgaard Andersen, Lars Juel Andersen, Mustafa Taskiran, Erik Simonsen, Ismail Gögenur

Abstract

Background: Depression following acute coronary syndrome (ACS) constitutes a serious and debilitating problem. Approximately one in five patients will develop significant depression following ACS and less severe depressive symptoms are even more frequent. Furthermore, anxiety symptoms and sleep-wake disturbances are frequent. The objective of the MEDACIS trial is to investigate whether prophylactic treatment with melatonin has a preventive effect on depression, depressive and anxiety symptoms, sleep, and circadian disturbances following ACS.

Methods/design: "The effect of MElatonin and Depressive symptoms, Anxiety, CIrcadian and Sleep disturbances in patients after acute coronary syndrome" trial (MEDACIS) is a multicenter, double-blinded, placebo-controlled, randomized clinical trial. A total of 240 patients with ACS and no depressive symptoms will be included in the trial for treatment with either 25 mg melatonin or placebo for a 12-week period. Development and severity of depressive symptoms will be evaluated using Major Depression Inventory every 2 weeks with the purpose of investigating the potential preventive effect of melatonin on depressive symptoms.

Discussion: Previously, only selective serotonin reuptake inhibitors (SSRIs) have been investigated in a primary preventive setup in patients following ACS. However, SSRIs are associated with several side effects. An ideal intervention would constitute the highest degree of prevention of depressive symptoms with the lowest risk of side effects. In this regard, melatonin may have advantages due to its low toxicity as well as its proven anxiolytic and hypnotic effects.

Trial registration: ClinicalTrials.gov, Identifier: NCT02451293 . Registered on 12 May 2015. EudraCT nr. 2015-002116-32.

Keywords: Acute coronary syndrome; Anxiety; Circadian rhythm; Depression; Melatonin; Sleep disturbances.

Figures

Fig. 1
Fig. 1
MElatonin on Depressive symptoms, Anxiety, CIrcadian and Sleep disturbances (MEDACIS) trial. Potential effects of exogenous melatonin intervention
Fig. 2
Fig. 2
MElatonin on Depressive symptoms, Anxiety, CIrcadian and Sleep disturbances (MEDACIS) CONSORT diagram. Consolidated Standards of Reporting Trials (CONSORT) diagram for the MEDACIS trial
Fig. 3
Fig. 3
MElatonin on Depressive symptoms, Anxiety, CIrcadian and Sleep disturbances (MEDACIS) Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure. SPIRIT figure for the MEDACIS trial

References

    1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442. doi: 10.1371/journal.pmed.0030442.
    1. White HD, Chew DP. Acute myocardial infarction. Lancet. 2008;372:570–84. doi: 10.1016/S0140-6736(08)61237-4.
    1. Koch MB, Johnsen NF, Davidsen M, Juel K. Hjertekarsygdomme i 2011 incidens, prævalens og dødelighed samt udvikling siden 2002. 5-1-2014. . Accessed 3 Feb 2017. Statens Institut for Folkesundhed, Syddansk Universitet for Hjerteforeningen. Ref Type: Report.
    1. Thombs BD, Bass EB, Ford DE, Stewart KJ, Tsilidis KK, Patel U, et al. Prevalence of depression in survivors of acute myocardial infarction. J Gen Intern Med. 2006;21:30–8. doi: 10.1111/j.1525-1497.2005.00269.x.
    1. Jiang W, Krishnan RR, O’Connor CM. Depression and heart disease: evidence of a link, and its therapeutic implications. CNS Drugs. 2002;16:111–27. doi: 10.2165/00023210-200216020-00004.
    1. Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation. 2014;129:1350–69. doi: 10.1161/CIR.0000000000000019.
    1. Meijer A, Conradi HJ, Bos EH, Thombs BD, van Melle JP, de Jonge P. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis of 25 years of research. Gen Hosp Psychiatry. 2011;33:203–16. doi: 10.1016/j.genhosppsych.2011.02.007.
    1. Lichtman JH, Bigger JT, Jr, Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lesperance F, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation. 2008;118:1768–75. doi: 10.1161/CIRCULATIONAHA.108.190769.
    1. Mavrides N, Nemeroff C. Treatment of depression in cardiovascular disease. Depress Anxiety. 2013;30:328–41. doi: 10.1002/da.22051.
    1. Strik JJ, Honig A, Lousberg R, Denollet J. Sensitivity and specificity of observer and self-report questionnaires in major and minor depression following myocardial infarction. Psychosomatics. 2001;42:423–8. doi: 10.1176/appi.psy.42.5.423.
    1. Denollet J, Strik JJ, Lousberg R, Honig A. Recognizing increased risk of depressive comorbidity after myocardial infarction: looking for 4 symptoms of anxiety-depression. Psychother Psychosom. 2006;75:346–52. doi: 10.1159/000095440.
    1. Lane D, Carroll D, Ring C, Beevers DG, Lip GY. The prevalence and persistence of depression and anxiety following myocardial infarction. Br J Health Psychol. 2002;7:11–21. doi: 10.1348/135910702169321.
    1. Mayou RA, Gill D, Thompson DR, Day A, Hicks N, Volmink J, et al. Depression and anxiety as predictors of outcome after myocardial infarction. Psychosom Med. 2000;62:212–9. doi: 10.1097/00006842-200003000-00011.
    1. Roest AM, Martens EJ, Denollet J, de Jonge P. Prognostic association of anxiety post myocardial infarction with mortality and new cardiac events: a meta-analysis. Psychosom Med. 2010;72:563–9. doi: 10.1097/PSY.0b013e3181dbff97.
    1. Celano CM, Millstein RA, Bedoya CA, Healy BC, Roest AM, Huffman JC. Association between anxiety and mortality in patients with coronary artery disease: a meta-analysis. Am Heart J. 2015;170:1105–15. doi: 10.1016/j.ahj.2015.09.013.
    1. Watkins LL, Blumenthal JA, Carney RM. Association of anxiety with reduced baroreflex cardiac control in patients after acute myocardial infarction. Am Heart J. 2002;143:460–6. doi: 10.1067/mhj.2002.120404.
    1. Young EA, Abelson JL, Cameron OG. Effect of comorbid anxiety disorders on the hypothalamic-pituitary-adrenal axis response to a social stressor in major depression. Biol Psychiatry. 2004;56:113–20. doi: 10.1016/j.biopsych.2004.03.017.
    1. von Känel R, Kudielka BM, Schulze R, Gander ML, Fischer JE. Hypercoagulability in working men and women with high levels of panic-like anxiety. Psychother Psychosom. 2004;73:353–60. doi: 10.1159/000080388.
    1. Grace SL, Abbey SE, Irvine J, Shnek ZM, Stewart DE. Prospective examination of anxiety persistence and its relationship to cardiac symptoms and recurrent cardiac events. Psychother Psychosom. 2004;73:344–52. doi: 10.1159/000080387.
    1. Coryell VT, Ziegelstein RC, Hirt K, Quain A, Marine JE, Smith MT. Clinical correlates of insomnia in patients with acute coronary syndrome. Int Heart J. 2013;54:258–65. doi: 10.1536/ihj.54.258.
    1. Morin CM, Ware JC. Sleep and psychopathology. Appl Prev Psychol. 1996;5:211–24. doi: 10.1016/S0962-1849(96)80013-8.
    1. Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res. 2003;37:9–15. doi: 10.1016/S0022-3956(02)00052-3.
    1. Lopez-Jimenez F, Sert Kuniyoshi FH, Gami A, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. Chest. 2008;133:793–804. doi: 10.1378/chest.07-0800.
    1. Leineweber C, Kecklund G, Janszky I, Akerstedt T, Orth-Gomer K. Poor sleep increases the prospective risk for recurrent events in middle-aged women with coronary disease. The Stockholm Female Coronary Risk Study. J Psychosom Res. 2003;54:121–7. doi: 10.1016/S0022-3999(02)00475-0.
    1. Srinivasan V, Pandi-Perumal SR, Trakht I, Spence DW, Hardeland R, Poeggeler B, et al. Pathophysiology of depression: role of sleep and the melatonergic system. Psychiatry Res. 2009;165:201–14. doi: 10.1016/j.psychres.2007.11.020.
    1. Carney CE, Segal ZV, Edinger JD, Krystal AD. A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. J Clin Psychiatry. 2007;68:254–60. doi: 10.4088/JCP.v68n0211.
    1. van Straten A, Geraedts A, Verdonck-de Leeuw I, Andersson G, Cuijpers P. Psychological treatment of depressive symptoms in patients with medical disorders: a meta-analysis. J Psychosom Res. 2010;69:23–32. doi: 10.1016/j.jpsychores.2010.01.019.
    1. Hackett ML, Anderson CS, House A, Halteh C. Interventions for preventing depression after stroke. Cochrane Database Syst Rev. 2008;3:CD003689.
    1. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev. 2005;9:11–24. doi: 10.1016/j.smrv.2004.08.001.
    1. Cardinali DP, Srinivasan V, Brzezinski A, Brown GM. Melatonin and its analogs in insomnia and depression. J Pineal Res. 2012;52:365–75. doi: 10.1111/j.1600-079X.2011.00962.x.
    1. Andersen LP, Werner MU, Rosenberg J, Gogenur I. A systematic review of peri-operative melatonin. Anaesthesia. 2014;69(10):1163–71.
    1. Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep Med Rev. 2005;9:25–39. doi: 10.1016/j.smrv.2004.05.002.
    1. Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev. 2005;9:41–50. doi: 10.1016/j.smrv.2004.06.004.
    1. Yang Y, Sun Y, Yi W, Li Y, Fan C, Xin Z, et al. A review of melatonin as a suitable antioxidant against myocardial ischemia-reperfusion injury and clinical heart diseases. J Pineal Res. 2014;57:357–66. doi: 10.1111/jpi.12175.
    1. Zhdanova IV. Melatonin as a hypnotic: pro. Sleep Med Rev. 2005;9:51–65. doi: 10.1016/j.smrv.2004.04.003.
    1. Reiter RJ, Tan DX, Osuna C, Gitto E. Actions of melatonin in the reduction of oxidative stress. A review. J Biomed Sci. 2000;7:444–58. doi: 10.1007/BF02253360.
    1. Hansen MV, Andersen LT, Madsen MT, Hageman I, Rasmussen LS, Bokmand S, et al. Effect of melatonin on depressive symptoms and anxiety in patients undergoing breast cancer surgery: a randomized, double-blind, placebo-controlled trial. Breast Cancer Res Treat. 2014;145:683–95. doi: 10.1007/s10549-014-2962-2.
    1. Madsen MT, Hansen MV, Andersen LT, Hageman I, Rasmussen LS, Bokmand S, et al. Effect of melatonin on sleep in the perioperative period after breast cancer surgery: a randomized, double-blind, placebo-controlled trial. J Clin Sleep Med. 2016;12(2):225–33.
    1. Hansen MV, Madsen MT, Andersen LT, Hageman I, Rasmussen LS, Bokmand S, et al. Effect of melatonin on cognitive function and sleep in relation to breast cancer surgery: a randomized, double-blind, placebo-controlled trial. Int J Breast Cancer. 2014;2014:416531. doi: 10.1155/2014/416531.
    1. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8:e63773. doi: 10.1371/journal.pone.0063773.
    1. Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ. 2006;332:385–93. doi: 10.1136/bmj.38731.532766.F6.
    1. Hansen MV, Halladin NL, Rosenberg J, Gogenur I, Moller AM. Melatonin for pre- and postoperative anxiety in adults. Cochrane Database Syst Rev. 2015;4:CD009861.
    1. Hansen MV, Danielsen AK, Hageman I, Rosenberg J, Gogenur I. The therapeutic or prophylactic effect of exogenous melatonin against depression and depressive symptoms: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2014;24:1719–28. doi: 10.1016/j.euroneuro.2014.08.008.
    1. Wilson SJ, Nutt DJ, Alford C, Argyropoulos SV, Baldwin DS, Bateson AN, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010;24:1577–601. doi: 10.1177/0269881110379307.
    1. Andersen LP, Gogenur I, Rosenberg J, Reiter RJ. The safety of melatonin in humans. Clin Drug Investig. 2016;36:169–75. doi: 10.1007/s40261-015-0368-5.
    1. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60:1581–98. doi: 10.1016/j.jacc.2012.08.001.
    1. Olsen LR, Mortensen EL, Bech P. Prevalence of major depression and stress indicators in the Danish general population. Acta Psychiatr Scand. 2004;109:96–103. doi: 10.1046/j.0001-690X.2003.00231.x.
    1. Olsen LR, Jensen DV, Noerholm V, Martiny K, Bech P. The internal and external validity of the Major Depression Inventory in measuring severity of depressive states. Psychol Med. 2003;33:351–6. doi: 10.1017/S0033291702006724.
    1. Bech P, Rasmussen NA, Olsen LR, Noerholm V, Abildgaard W. The sensitivity and specificity of the Major Depression Inventory, using the Present State Examination as the index of diagnostic validity. J Affect Disord. 2001;66:159–64. doi: 10.1016/S0165-0327(00)00309-8.
    1. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361–70. doi: 10.1111/j.1600-0447.1983.tb09716.x.
    1. Thombs BD, Magyar-Russell G, Bass EB, Stewart KJ, Tsilidis KK, Bush DE, et al. Performance characteristics of depression screening instruments in survivors of acute myocardial infarction: review of the evidence. Psychosomatics. 2007;48:185–94. doi: 10.1176/appi.psy.48.3.185.
    1. Sadeh A. The role and validity of actigraphy in sleep medicine: an update. Sleep Med Rev. 2011;15:259–67. doi: 10.1016/j.smrv.2010.10.001.
    1. Madsen MT, Rosenberg J, Gogenur I. Actigraphy for measurement of sleep and sleep-wake rhythms in relation to surgery. J Clin Sleep Med. 2013;9:387–94.
    1. Madsen MT, Huang C, Gogenur I. Actigraphy for measurements of sleep in relation to oncological treatment of patients with cancer: a systematic review. Sleep Med Rev. 2015;20:73–83.
    1. Carpenter JS, Andrykowski MA. Psychometric evaluation of the Pittsburgh Sleep Quality Index. J Psychosom Res. 1998;45:5–13. doi: 10.1016/S0022-3999(97)00298-5.
    1. Archer SN, Robilliard DL, Skene DJ, Smits M, Williams A, Arendt J, et al. A length polymorphism in the circadian clock gene Per3 is linked to delayed sleep phase syndrome and extreme diurnal preference. Sleep. 2003;26:413–5.
    1. Artioli P, Lorenzi C, Pirovano A, Serretti A, Benedetti F, Catalano M, et al. How do genes exert their role? Period 3 gene variants and possible influences on mood disorder phenotypes. Eur Neuropsychopharmacol. 2007;17:587–94. doi: 10.1016/j.euroneuro.2007.03.004.
    1. Dijk DJ, Archer SN. PERIOD3, circadian phenotypes, and sleep homeostasis. Sleep Med Rev. 2010;14:151–60. doi: 10.1016/j.smrv.2009.07.002.
    1. Littner M, Kushida CA, Anderson WM, Bailey D, Berry RB, Davila DG, et al. Practice parameters for the role of actigraphy in the study of sleep and circadian rhythms: an update for 2002. Sleep. 2003;26:337–41.
    1. Schulz KF, Grimes DA. Multiplicity in randomised trials I: endpoints and treatments. Lancet. 2005;365:1591–5. doi: 10.1016/S0140-6736(05)66461-6.
    1. Schulz KF, Grimes DA. Multiplicity in randomised trials II: subgroup and interim analyses. Lancet. 2005;365:1657–61. doi: 10.1016/S0140-6736(05)66516-6.
    1. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1–100. doi: 10.1111/j.1600-0447.1987.tb10566.x.
    1. Lindstrom E, Lewander T, Malm U, Malt UF, Lublin H, Ahlfors UG. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat) Nord J Psychiatry. 2001;55(Suppl 44):5–69.
    1. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials. 2010;11:32. doi: 10.1186/1745-6215-11-32.
    1. Osler M, Martensson S, Wium-Andersen IK, Prescott E, Andersen PK, Jorgensen TS, et al. Depression after first hospital admission for acute coronary syndrome: a study of time of onset and impact on survival. Am J Epidemiol. 2016;183:218–26. doi: 10.1093/aje/kwv227.
    1. Czarny MJ, Arthurs E, Coffie DF, Smith C, Steele RJ, Ziegelstein RC, et al. Prevalence of antidepressant prescription or use in patients with acute coronary syndrome: a systematic review. PLoS One. 2011;6:e27671. doi: 10.1371/journal.pone.0027671.
    1. Hansen BH, Hanash JA, Rasmussen A, Hansen JF, Andersen NL, Nielsen OW, et al. Effects of escitalopram in prevention of depression in patients with acute coronary syndrome (DECARD) J Psychosom Res. 2012;72:11–6. doi: 10.1016/j.jpsychores.2011.07.001.
    1. Hansen BH, Hanash JA, Rasmussen A, Hansen JF, Birket-Smith M. Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD) Trials. 2009;10:20. doi: 10.1186/1745-6215-10-20.
    1. Cooke MJ, Waring WS. Citalopram and cardiac toxicity. Eur J Clin Pharmacol. 2013;69:755–60. doi: 10.1007/s00228-012-1408-1.
    1. Chen WY, Giobbie-Hurder A, Gantman K, Savoie J, Scheib R, Parker LM, et al. A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes. Breast Cancer Res Treat. 2014;145:381–8. doi: 10.1007/s10549-014-2944-4.
    1. Innominato PF, Lim AS, Palesh O, Clemons M, Trudeau M, Eisen A, et al. The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. Support Care Cancer. 2016;24(3):1097–105.
    1. Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev. 2002;2:CD001520.
    1. Loo H, Hale A, D’haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol. 2002;17:239–47. doi: 10.1097/00004850-200209000-00004.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit